Hypophosphatemia during KRT linked to fewer ventilator-free days in critically ill patients
This post hoc observational study analyzed data from 1,942 critically ill patients in the STARRT-AKI trial who received kidney replacement therapy (KRT). Among them, 634 developed hypophosphatemia (serum phosphate <0.7 mmol/L) during KRT. The primary outcome was ventilator-free days (VFD) at 28 days.
Incident hypophosphatemia was associated with fewer VFD (beta = 0.91; 95% CI, 0.87-0.95; P < 0.001). Severe hypophosphatemia (<0.5 mmol/L) showed a similar association (beta = 0.87; 95% CI, 0.82-0.93; P < 0.001). The combined outcome of 28-day survival and fewer ventilator days was 27% lower in patients with incident hypophosphatemia and 25% lower in those with severe hypophosphatemia.
No association was found between hypophosphatemia and 90-day mortality or KRT dependence at 90 days. Safety data were not reported.
Key limitations include selection bias and unmeasured confounding. As a post hoc observational analysis, these findings do not establish causality. Clinicians should interpret the association cautiously and consider monitoring phosphate levels during KRT, but randomized trials are needed to confirm any causal relationship.